Chairman to Help Progress Commercialisation Phase

Pertinax Pharma has announced the appointment of Nigel Brooksby as chairman of the company following the recent launch of its primary product for the wound care, medical device, dental and veterinary markets.

A spin-out of the University of Bristol, the company’s Pertinax® technology enables controlled and sustained release of the antimicrobial, chlorhexidine (CHX).

Highly regarded as an experienced businessman and entrepreneur in the life sciences arena, Nigel Brooksby has been involved in raising significant investment and undertaken many projects in partnering biotech companies with big pharma. A non-executive director at Porton Biopharma, a director of Stabilitech Pharma, a non-executive director at Chronos Therapeutics and chairman of both Clinical Insights Ltd and Neurocentrx Pharma, he has also held senior appointments in Wellcome (now GSK), in Pfizer and the Sanofi Group in the UK and Ireland.

A past president and lifetime member of the Association of the British Pharmaceutical Industry (ABPI) he holds several academic, charity and life sciences chairmanships and senior board positions including chairman of the Pharmaceutical Directors Club (PDC).

“I am delighted to take on this position at such a pivotal phase in the company’s development, “Mr Brooksby said. “Pertinax has enormous market potential in multiple fields. We are already in talks with several manufacturers and over the course of the next twelve months, we confidently expect to have applications of Pertinax in development for use in wound care, veterinary and dental products.”

Michele Barbour, Founder and CSO of Pertinax Pharma commented: “We are delighted that Nigel has chosen to join our board. His unparalleled experience in the pharmaceutical and related industries, his long established industry connections and his experience with early stage biomedical companies make him the ideal individual for the tasks at hand.”